Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing new medicines to improve patient outcomes. The company utilizes genetic and genomic technologies to inform its drug discovery and clinical trials. Vanda's product portfolio includes Fanapt® (iloperidone), an atypical antipsychotic approved for schizophrenia, and Hetlioz® (tasimelteon), a treatment for Non24 Hour Sleep Wake Disorder. The company is also developing tradipitant for atopic dermatitis and gastroparesis, and pursuing additional indications for tasimelteon. Vanda is based in Washington, D.C.
- Website
- www.vandapharma.com
- Issuer profile
- All listings